Structural and functional insights into human vitamin K epoxide reductase and vitamin K epoxide reductase-like

Critical Reviews in Biochemistry and Molecular Biology

Volumn 48, Issue 4, 2013, Pages 357-372

  Van Horn, Wade D ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Membrane protein structural biology; Personalized medicine; Vitamin K; Vitamin K epoxide reductase; Vitamin K epoxide reductase like 1; Warfarin

Indexed keywords

FARNOQUINONE; MEMBRANE PROTEIN; MENATETRENONE; PHYTOMENADIONE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K EPOXIDE REDUCTASE LIKE1; WARFARIN;

BLOOD CLOTTING; BONE METABOLISM; CANCER INCIDENCE; CANCER THERAPY; CARBOXYLATION; CHROMOSOME 16; CHROMOSOME 7; CRYSTAL STRUCTURE; DRUG BINDING SITE; ENZYME ACTIVITY; ENZYME MECHANISM; GENE DUPLICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GLYCOSYLATION; HEMOSTASIS; HOMEOSTASIS; HUMAN; IMMUNOBLOTTING; MEDICAL PRACTICE; MEMBRANE STRUCTURE; MITOCHONDRIAL RESPIRATION; MODULATION; MUTAGENESIS; MYCOBACTERIUM TUBERCULOSIS; NEOPLASM; NONHUMAN; OPEN READING FRAME; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHYLOGENY; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SYNECHOCOCCUS;

EID: 84880914753     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2013.791659     Document Type: Review

References (108)

1. Aithal GP, Day CP, Kesteven PJL, Daly AK. (1999). Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-19. (Pubitemid 29103806)
2. Albert C, Wilson LK, Mineau P, et al. (2010). Anticoagulant rodenticides in three owl species from Western Canada, 1988-2003. Arch Environ Con Tox 58:451-9.
3. Bell RG, Matschiner JT. (1970). Vitamin K activity of phylloquinone oxide. Biochem Biophys 141:473-6.
4. Bell RG, Matschiner JT. (1972). Warfarin and the inhibition of vitamin K activity by an oxide metabolite. Nature 237:32-3.
5. Berkner KL. (2008). Vitamin K-dependent carboxylation. Vitam Horm 78:131-56.
6. Bogdanov M, Dowhan W. (2012). Lipid-dependent generation of dual topology for a membrane protein. J Biol Chem 287:37939-48.
7. Booth SL. (2012). Vitamin K: food composition and dietary intakes. Food Nutr Res 56:1-5.
8. Bryan PN, Orban J. (2010). Proteins that switch folds. Curr Opin Struct Biol 20:482-88.
9. Cain D, Hutson SM, Wallin R. (1997). Assembly of the warfarinsensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. J Biol Chem 272:29068-75. (Pubitemid 27498194)
10. Chen Y-j, Pornillos O, Lieu S, et al. (2007). X-ray structure of EmrE supports dual topology model. Proc Natl Acad Sci USA 104: 18999-9004.
11. Chivers PT, Laboissiere MCA, Raines RT. (1996). The CXXC motif: imperatives for the formation of native disulfide bonds in the cell. EMBO J 15:2659-67. (Pubitemid 26176244)
12. Choonara IA, Cholerton S, Haynes BP, et al. (1986). Stereoselective interaction between the R-enantiomer of warfarin and cimetidine. Br J Clin Pharmacol 21:271-7. (Pubitemid 17168698)
13. Chu P-H, Huang T-Y, Williams J, Stafford DW. (2006). Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2. Proc Natl Acad Sci USA 103:19308-13. (Pubitemid 46026028)
14. Davidson RT, Foley AL, Engelke JA, Suttie JW. (1998). Conversion of dietary phylloquinone to tissue menaquinone-4 in rats is not dependent on gut bacteria. J Nutr 128:220-3. (Pubitemid 28124990)
15. Deerfield D, Davis CH, Wymore T, et al. (2006). Quantum chemical study of the mechanism of action of vitamin K epoxide reductase (VKOR). Int J Quant Chem 106:2944-52. (Pubitemid 44726732)
16. Dialameh GH, Yekundi KG, Olson RE. (1970). Enzymatic alkylation of menaquinone-0 to menaquinones by microsomes from chick liver. Biochim Biophys Acta 223:332-8.
17. Dutton RJ, Boyd D, Berkmen M, Beckwith J. (2008). Bacterial species exhibit diversity in their mechanisms and capacity for protein disulfide bond formation. Proc Natl Acad Sci USA 105:11933-8.
18. Dutton RJ, Wayman A, Wei J-R, et al. (2010). Inhibition of bacterial disulfide bond formation by the anticoagulant warfarin. Proc Natl Acad Sci USA 107:297-301.
19. Eby C. (2012). Warfarin pharmacogenetics: does more accurate dosing benefit patients? Sem Thromb Hemost 38:661-6.
20. Fasco MJ, Principe LM. (1982). R-and S-warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat. J Biol Chem 257:4894-901. (Pubitemid 12063183)
21. Fasco MJ, Principe LM, Walsh WA, Friedman PA. (1983). Warfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomest. Biochemistry 22:5655-60. (Pubitemid 14212084)
22. Ferland G. (2012a). The discovery of vitamin K and its clinical applications. Annal Nutr Metab 61:213-18.
23. Ferland G. (2012b). Vitamin K, an emerging nutrient in brain function. Biofactors 38:151-7.
24. Ferland G. (2012c). Vitamin K and the nervous system: an overview of its actions. Adv Nutr 3:204-12.
25. Fredericks WJ, McGarvey T, Wang H, et al. (2011). TERE1 (UBIAD1) modulates cell cholesterol: implications for tumor progression. DNA Cell Biol 30:851-64.
26. Fregin A, Rost S, Wolz W, et al. (2002). Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin Kdependent clotting factors to the centromeric region of chromosome 16. Blood 100:3229-32. (Pubitemid 35217071)
27. Goodstadt L, Ponting CP. (2004). Vitamin K epoxide reductase: homolgy, active site and catalytic mechanism. Trends Biochem Sci 29:289-92. (Pubitemid 38968759)
28. Hartmann E, Rapoport TA, Lodish HF. (1989). Predicting the orientation of eukaryotic membrane-spanning protein. Proc Natl Acad Sci USA 86:5786-90. (Pubitemid 19217538)
29. Hatahet F, Ruddock LW. (2009). Protein disulfide isomerase: A critical evaluation of its function in disulfide bond formation. Antioxid Redox Sign 11:2807-50.
30. Hauschka PV, Lian JB, Gallop PM. (1975). Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci USA 72:3925-9.
31. Hebling CM, Morgan CR, Stafford DW. (2010). Conformational Analysis of Membrane Proteins in Phospholipid Bilayer Nanodiscs by Hydrogen Exchange Mass Spectrometry. Anal Chem 82:5415-19.
32. Hirsh J, Fuster V, Ansell J, Halperin JL. (2003). American heart association/american college of cardiology foundation guide to warfarin therapy. J Am Coll Cardiol 41:1633-52. (Pubitemid 36543387)
33. Hodroge A, Matagrin B, Moreau C, et al. (2012). VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity. J Thromb Haemost 10: 2535-43.
34. Holmes RW, Love J. (1952). Suicide attempt with warfarin, a bishydroxycoumarin-like rodenticide. J Am Med Assoc 148:935-7.
35. Jin D-Y, Tie J-K, Stafford DW. (2007). The conversion of vitamin K epoxide to vitamin K quinone and vitamin K quinone to vitamin K hydroquinone uses the same active site cysteines. Biochemistry 46: 7279-83. (Pubitemid 46974001)
36. Johan L, van Haarlem M, Soute BA, Vermeer C. (1987). Vitamin Kdependent carboxylase. Possible role for thioredoxin in the reduction of vitamin K metabolites in liver. FEBBS Lett 222:353-7.
37. Johnson JA. (2012). Warfarin pharmacogenetics: a rising tide for its clinical value. Circulation 125:1964-6.
38. Jordan P, Fromme P, Witt HT, et al. (2001). Three-dimensional structure of cyanobacterial photosystem I at 2.5A° resolution. Nature 411: 909-17. (Pubitemid 32601481)
39. Kamali F, Wynne H. (2010). Pharmacogenetics of warfarin. Annu Rev Med 61:63-75.
40. Karasawa S, Azuma M, Kasama T, et al. (2013). Vitamin K2 covalently binds to Bak and induces Bak-mediated apoptosis. Mol Pharmacol 83:613-20.
41. Katzen F, Beckwith J. (2003). Role and location of the unusual redoxactive cysteines in the hydrophobic domain of the transmembrane electron transporter DsbD. Proc Natl Acad Sci USA 100:10471-6. (Pubitemid 37071902)
42. Kellum JM. (1952). Warfarin for suicide. J Am Med Assoc 148:1443.
43. Kohn MH, Pelz H-J. (2000). A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans. Blood 96:1996-8. (Pubitemid 30661089)
44. Laurindo F, Pescatore L, Fernandes DC. (2012). Protein disulfide isomerase in redox cell signaling and homeostasis. Free Radic Biol Med 52:1954-69.
45. Li J, Lin JC, Wang H, et al. (2003). Novel role of vitamin k in preventing oxidative injury to developing oligodendrocytes and neurons. J Neurosci 23:5816-26. (Pubitemid 36807861)
46. Li T, Chang C-Y, Jin D-Y, et al. (2004). Identification of the gene for vitamin K epoxide reductase. Nature 427:541-4. (Pubitemid 38209111)
47. Li W, Schulman S, Dutton RJ, et al. (2010). Structure of a bacterial homologue of vitamin K epoxide reductase. Nature 463:507-12.
48. Link KP. (1959). The discovery of dicumarol and its sequels. Circulation 19:97-107.
49. Lu J, Deutsch C. (2001). Pegylation: A method for assessing topological accessibilities in Kv1.3. Biochemistry 40:13288-301. (Pubitemid 33043545)
50. Matsuo Y, Nishinaka Y, Suzuki S, et al. (2004). TMX, a human transmembrane oxidoreductase of the thioredoxin family: the possible role in disulfide-linked protein folding in the endoplasmic reticulum. Arch Biochem Biophys 423:81-7. (Pubitemid 38198216)
51. Mercer PF, Chambers RC. (2012). Coagulation and coagulation signalling in fibrosis. Biochim Biophys Acta 12:[Epub ahead of print]. doi: 10.1016/j.bbadis.2012.12.013.
52. Nakagawa K, Hirota Y, Sawada N, et al. (2010). Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature 468:117-21.
53. Mummah-Schendel L, Suttie J. (1986). Serum phylloquinone concentrations in a normal adult population. The American J Clin Nutr 44: 686-9. (Pubitemid 17194675)
54. Nimptsch K, Rohrmann S, Kaaks R, Linseisen J. (2010). Dietary vitamin K intake in relation to cancer incidence and mortality: results from the heidelberg cohort of the european prospective investigation into cancer and nutrition (EPIC-Heidelberg) 1-3. Am J Clin Nutr 91: 1348-58.
55. Okano T, Shimomura Y, Yamane M, et al. (2008). Conversion of phylloquinone (Vitamin K1) into menaquinone-4 (Vitamin K2) in mice: two possible routes for menaquinone-4 accumulation in cerebra of mice. J Biol Chem 283:11270-9.
56. Oldenburg J, Marinova M, Müller-Reible C, Watzka M. (2008). The vitamin K cycle. Vitam Horm 78:35-62.
57. Ortega AL, Mena S, Estrela JM. (2011). Glutathione in Cancer Cell Death. Cancers 3:1285-310.
58. Pelz HJ, Rost S, Hünerberg M, et al. (2005). The genetic basis of resistance to anticoagulants in rodents. Genetics 170:1839-47. (Pubitemid 41362835)
59. Quan S, Schneider I, Pan J, et al. (2007). The CXXC motif is more than a redox rheostat. J Biol Chem 282:28823-33. (Pubitemid 47606028)
60. Rishavy MA, Usubalieva A, Hallgren KW, Berkner KL. (2011). Novel insight into the mechanism of the vitamin K oxidoreductase (VKOR): electron relay through Cys43 and Cys51 reduces VKOR to allow vitamin K reduction and facilitation of vitamin K-dependent protein carboxylation. J Biol Chem 286:7267-78.
61. Robertson HM. (2004). Genes encoding vitamin-K epoxide reductase are present in Drosophila and trypanosomatid protists. Genetics 168: 1077-80. (Pubitemid 39491481)
62. Romero EE, Velazquez-Estades LJ, Deo R, et al. (1998). Cloning of rat vitamin K-dependent g-glutamyl carboxylase and developmentally regulated gene expression in postimplantation embryos. Exp Cell Res 243:334-46. (Pubitemid 28488844)
63. Rost S, Fregin A, Ivaskevicius V, et al. (2004). Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537-41. (Pubitemid 38209110)
64. Rost S, Fregin A, Hünerberg M, et al. (2005). Site-directed mutagenesis of coumarin-type anticoagulantsensitive. Thromb Haemost 94:780-6.
65. Rost S, Pelz H-J, Menzel S, et al. (2009). Novel mutations in the VKORC1 gene of wild rats and mice-a response to 50 years of selection pressure by warfarin? BMC Genet 10:4.
66. Roth D, Lynes E, Riemer J, et al. (2010). A di-arginine motif contributes to the ER localization of the type I transmembrane ER oxidoreductase TMX4. Biochem J 425:195-205.
67. Sato Y, Inaba K. (2012). Disulfide bond formation network in the three biological kingdoms, bacteria, fungi and mammals. FEBS Journal 279:2262-71.
68. Schaafhausen A, Rost S, Oldenburg J, et al. (2011). Identification of VKORC1 interaction partners by split-ubiquitin system and coimmunoprecipitation. J Biol Chem 105:285-94.
69. Schulman S, Wang B, Li W, et al. (2010). Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners. Proc Natl Acad Sci USA 107:15027-32.
70. Seppälä S, Slusky JS, Lloris-Garcerá P, et al. (2010). Control of membrane protein topology by a single C-terminal residue. Science 328:1698-700.
71. Shao S, Hegde RS. (2011). Membrane protein insertion at the endoplasmic reticulum. Annu Rev Cell Dev Biol 27:25-56.
72. Shearer MJ, Newman P. (2008). Metabolism and cell biology of vitamin K. Thromb Haemost 100:530-47.
73. Sigiura Y, Araki K, Iemura S, et al. (2010). Novel thioredoxin-related transmembrane protein TMX4 has reductase activity. J Biol Chem 285:7135-42.
74. Silverman RB. (1981). Chemical model studies for the mechanism of vitamin K epoxide reductase. J Am Chem Soc 103:5939-41. (Pubitemid 12209188)
75. Silverman RB, Nandi DL. (1988). Reduced thioredoxin: A possible physiological cofactor for vitamin K epoxide reductase. Further support for an active site disulfide. Biochem Biophys Res Commun 155:1248-54.
76. Skolarus LE, Morgenstern LB, Froehlich JB, et al. (2011). Guidelinediscordant periprocedural interruptions in warfarin therapy. Circ Cardiovas Qual Outcomes 4:206-10.
77. Soute BA, Groenen-van Dooren MM, Holmgren A, et al. (1992). Stimulation of the dithiol-dependent reductases in the vitamin K cycle by the thioredoxin system. Strong synergistic effects with protein disulphideisomerase. Biochem J 281:255-9.
78. Spohn G, Kleinridders A, Wunderlich FT, et al. (2009). VKORC1 deficiency in mice causes early postnatal lethality due to severe bleeding. Thromb Haemost 101:1044-50.
79. Strahmann MA, Huebner CF, Link KP. (1941). Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. J Biol Chem 138:513-27.
80. Su AI, Wiltshire T, Batalov S, et al. (2004). A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 101:6062-7. (Pubitemid 38520528)
81. Sundaram KS, Lev M. (1988). Warfarin administration reduces synthesis of sulfatides and other sphingolipids in mouse brain. J Lipid Res 29: 1475-9. (Pubitemid 19013041)
82. Suttie JW. (1995). The importance of menaquinones in human nutrition. Annu Rev Nutr 15:399-417.
83. Tabb MM, Sun A, Zhou C, et al. (2003). Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 278:43919-27. (Pubitemid 37377131)
84. Thijssen HHW, Drittij-Reijnders MJ. (1994). Vitamin K distribution in rat tissues: dietary phylloquinone is a source of tissue menaquinone-4. Brit J Nutr 72:415-25. (Pubitemid 24293471)
85. Thijssen HHW, Drittij-Reijnders MJ. (1996). Vitamin K status in human tissues: tissue-specific accumulation of phylloquinone and menaquinone-4. Brit J Nutr 75:121-7. (Pubitemid 26059371)
86. Thijssen HHW, Janssen YP, Vervoort LT. (1994). Microsomal lipoamide reductase provides vitamin K epoxide reductase with reducing equivalents. Biochem J 297:277-80. (Pubitemid 24026418)
87. Tie J-K, Nicchitta C, von Heijne G, Stafford DW. (2005). Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/ cotranslocation. J Biol Chem 280:16410-16. (Pubitemid 40616771)
88. Tie J-K, Stafford DW. (2008). Structure and function of vitamin K epoxide reductase. Vitam Horm 78:103-30.
89. Tie J-K, Jin D-Y, Straight DL, Stafford DW. (2011). Functional study of the vitamin K cycle in mammalian cells. Blood 117:2967-74.
90. Tie J-K, Jin D-Y, Stafford DW. (2012a). Human vitamin k epoxide reductase and its bacterial homologue have different membrane topologies and reaction mechanisms. J Biol Chem 287:33945-55.
91. Tie J-K, Jin D-Y, Stafford DW. (2012b). Mycobacterium tuberculosis vitamin K epoxide reductase homologue supports vitamin kdependent carboxylation in mammalian cells. Antioxid Redox Sign 16:329-38.
92. Vervoort LM, Ronden JE, Thijssen HHW. (1997). The potent antioxidant activity of the vitamin K cycle in microsomal lipid peroxidation. Biochem Pharmacol 54:871-6. (Pubitemid 27404594)
93. von Heijne G. (1986). The distribution of positively charged residues in bacterial inner membrane proteins correlates with the transmembrane topology. EMBO J 5:3021-7.
94. von Heijne G. (2006). Membrane-protein topology. Nat Rev Molec Cell Biol 7:909-18. (Pubitemid 44871417)
95. Voora D, Koboldt DC, King CR, et al. (2010). A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in african americans. Clin Pharmacol Ther 87:445-51.
96. Vos M, Esposito G, Edirisinghe JN, et al. (2012). Vitamin K2 is a mitochondrial electron carrier that rescues pink1 deficiency. Science 336:1306-10.
97. Wajih N, Sane DC, Hutson SM, Wallin R. (2004). The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarinresistant rats. J Biol Chem 279:25276-83. (Pubitemid 38756780)
98. Wajih N, Hutson SM, Wallin R. (2006). siRNA silencing of calumenin enhances functional factor IX production. Blood 108:3757-60. (Pubitemid 44864556)
99. Wajih N, Hutson SM, Wallin R. (2007). Disulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum. A protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K1 2,3-epoxide reduction. J Biol Chem 282:2626-35. (Pubitemid 47076752)
100. Wallin R, Hutson SM, Cain D, et al. (2001). A molecular mechanism for genetic warfarin resistance in the rat. FASEB J 15:2542-4.
101. Wang X, Dutton RJ, Beckwith J, Boyd D. (2011). Membrane topology and mutational analysis of Mycobacterium tuberculosis VKOR, a protein involved in disulfide bond formation. Antioxid Redox Sign 14: 1413-20.
102. Westhofen P, Watzka M, Marinova M, et al. (2011). Human vitamin K 2,3-epoxide reductase complex subunit 1-like 1 (VKORC1L1) mediates vitamin K-dependent intracellular antioxidant function. J Biol Chem 286:15085-94.
103. Wilkinson B, Gilbert HF. (2004). Protein disulfide isomerase. Biochim Biophys Acta 1699:35-44. (Pubitemid 38680792)
104. Wilson CR, Sauer J-M, Carlson GP, et al. (2003). Species comparison of vitamin K1 2,3-epoxide reductase activity in vitro: kinetics and warfarin inhibition. Toxocology 189:191-8. (Pubitemid 36773855)
105. Wu S, Liu S, Davis CH, Stafford DW, et al. (2011). A hetero-dimer model for concerted action of vitamin K carboxylase and vitamin K reductase in vitamin K cycle. J Theoret Biol 279:143-9.
106. Wysowski DK, Nourjah P, Swartz L. (2007). Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 167:1414-19. (Pubitemid 47052441)
107. Yin T, Hanada H, Miyashita K, et al. (2008). No association between vitamin K epoxide reductase complex subunit 1-like 1 (VKORC1L1) and the variability of warfarin dose requirement in a Japanese patient population. Thromb Res 122:179-84. (Pubitemid 351754917)
108. Zimmerman A, Matschiner JT. (1974). Biochemical basis of hereditary resistance to warfarin in the rat. Biochem Pharmacol 23:1033-40.